The following is a description of some corporate transactions in which Bill Fabbri has represented clients:

Business Development Transactions

Represented biopharma company in $250 million license and collaboration agreement with another biopharma company

Represented biopharma company in amendment of $65 million license and research agreement, including return of rights to certain compounds and increase in royalty and milestone payments

Represented biopharma company in $29 million drug development joint venture with mid-sized pharmaceutical company, including licensing, financing and operating agreements

Represented biopharma company in $24 million multi-party consortium funded by Gates Foundation

Represented CRO in amendment to Clinical Development Agreement with pharmaceutical company to provide for tiered-royalty and $10 million in success-based milestones

Represented biopharma company in termination of drug development joint venture and reacquisition of full development, manufacturing and commercialization rights

Represented specialized clinical development company in multi-Phase clinical development agreement with biopharma company containing cash, restricted stock and royalty-based consideration.

Represented biopharma company in collaboration, supply and distribution agreement with South American distributor

Represented biopharma company in in-license of oral drug delivery technology from mid-sized pharma company for development of oral version of lead drug candidate

Represented biopharma company in $5 million exclusive license agreement for patent portfolio resolving potential interference and inventorship issues

Represented biopharma company in return of compound class under a research and license agreement

Represented biopharma company in freedom-to-operate license

Private Offerings

Represented biopharma company in $20 million equity line of credit

Represented biopharma company in 7 PIPEs of preferred stock and warrants and common stock and warrants raising a total of $50 million

Represented limited partnership in investment of up to $7 million of Series A preferred stock in medical device/diagnostic company

Represented drug delivery company in a private sale of $2 million of common stock

Represented VC in $13 million first round financing of telecom software start-up

Represented private QoS software developer in $25 million Series E Preferred Stock financing

Represented borrower in $7 million revolving credit facility with Fleet Bank

Public Offerings

Represented Issuers and Underwriters in aggregate of $575 million of public offerings of common stock, preferred stock and debt

Providing Corporate Legal Services to the Life Science Community
© 2012 Fabbri Law, LLC